All In Biotech

Drug Trial Radar · NCT04368585

Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

An Open-Label, 3-Period, Fixed-Sequence, Study to Examine the Effect of Aluminum Hydroxide/Magnesium Hydroxide/Simethicone and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Sep 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Jul 1, 2020

Primary completion

Aug 8, 2020

Study completion Aug 21, 2020

Sponsor

Lead sponsor
Spero TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To assess the effect of a single dose of aluminum hydroxide/magnesium hydroxide/simethicone and omeprazole on the pharmacokinetics (PK) of TBPM, following a single dose of TBPM-PI-HBr in healthy adult subjects.

Conditions

  • Healthy Volunteers

Interventions

  • Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)Drug

    Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.

  • 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)Drug

    20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.

  • OmeprazoleDrug

    40 mg (1 x 40 mg capsule) omeprazole administered QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  2. Area under the curve extrapolated to infinity (AUC0-∞).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  3. Percent of AUC0-inf extrapolated (AUC%extrap)Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  4. Maximum plasma concentration (Cmax).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  5. Time to the maximum plasma concentration (Tmax).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  6. Terminal elimination half-life (t½).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  7. Apparent total body clearance (CL/F)Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)
  8. Apparent volume of distribution during the terminal elimination phase after oral (extravascular) administration (Vz/F).Time frame: Day 2 (Periods 1 and 2) and Day 6 (Period 3)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical Facility

    Phoenix, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.